| Large scale production of recombinant human lactoferrin in the milk of transgenic cows PHC Van Berkel, MM Welling, M Geerts, HA van Veen, B Ravensbergen, ... Nature biotechnology 20 (5), 484-487, 2002 | 423 | 2002 |
| Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange AF Labrijn, JI Meesters, BECG de Goeij, ETJ van den Bremer, J Neijssen, ... Proceedings of the National Academy of Sciences 110 (13), 5145-5150, 2013 | 396 | 2013 |
| Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria PH Nibbering, E Ravensbergen, MM Welling, LA Van Berkel, ... Infection and Immunity 69 (3), 1469-1476, 2001 | 322 | 2001 |
| Structure and biological actions of lactoferrin JH Nuijens, PHC van Berkel, FL Schanbacher Journal of Mammary Gland Biology and Neoplasia 1, 285-295, 1996 | 267 | 1996 |
| Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells M Peipp, JJ Lammerts van Bueren, T Schneider-Merck, WWK Bleeker, ... Blood, The Journal of the American Society of Hematology 112 (6), 2390-2399, 2008 | 261 | 2008 |
| Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid … T Schneider-Merck, JJ Lammerts van Bueren, S Berger, K Rossen, ... The journal of immunology 184 (1), 512-520, 2010 | 258 | 2010 |
| High‐level expression of recombinant IgG in the human cell line PER. C6 D Jones, N Kroos, R Anema, B Van Montfort, A Vooys, S Kraats, E Helm, ... Biotechnology progress 19 (1), 163-168, 2003 | 255 | 2003 |
| Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose MJ Gramer, JJ Eckblad, R Donahue, J Brown, C Shultz, K Vickerman, ... Biotechnology and bioengineering 108 (7), 1591-1602, 2011 | 250 | 2011 |
| N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA PHC VAN BERKEL, EJM GEERTS, AH VAN VEEN, M MERICSKAY, ... Biochemical Journal 328 (1), 145-151, 1997 | 247 | 1997 |
| Recombinant production of mixtures of antibodies PHC Van Berkel, A Bout, T Logtenberg, RHP Brus US Patent 7,262,028, 2007 | 174 | 2007 |
| Glycosylated and unglycosylated human lactoferrins both bind iron and show identical affinities towards human lysozyme and bacterial lipopolysaccharide, but differ in their … PHC Van Berkel, MEJ Geerts, HA Van Veen, PM Kooiman, FR Pieper, ... Biochemical Journal 312 (1), 107-114, 1995 | 174 | 1995 |
| ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies F Zammarchi, S Corbett, L Adams, PC Tyrer, K Kiakos, N Janghra, ... Blood, The Journal of the American Society of Hematology 131 (10), 1094-1105, 2018 | 167 | 2018 |
| The role of N‐linked glycosylation in the protection of human and bovine lactoferrin against tryptic proteolysis HA Van Veen, MEJ Geerts, PHC Van Berkel, JH Nuijens European journal of biochemistry 271 (4), 678-684, 2004 | 147 | 2004 |
| Enhanced Th1 response to Staphylococcus aureus infection in human lactoferrin-transgenic mice C Guillén, IB McInnes, DM Vaughan, S Kommajosyula, PHC Van Berkel, ... The Journal of Immunology 168 (8), 3950-3957, 2002 | 140 | 2002 |
| N-and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits K Koles, PHC van Berkel, FR Pieper, JH Nuijens, MLM Mannesse, ... Glycobiology 14 (1), 51-64, 2004 | 139 | 2004 |
| ADCT-301, a pyrrolobenzodiazepine (PBD) dimer–containing antibody–drug conjugate (ADC) targeting CD25-expressing hematological malignancies MJ Flynn, F Zammarchi, PC Tyrer, AU Akarca, N Janghra, CE Britten, ... Molecular cancer therapeutics 15 (11), 2709-2721, 2016 | 128 | 2016 |
| Anti-galactose-α-1, 3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains JJL van Bueren, T Rispens, S Verploegen, T van der Palen-Merkus, ... Nature biotechnology 29 (7), 574-576, 2011 | 126 | 2011 |
| N‐linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG PHC van Berkel, J Gerritsen, G Perdok, J Valbjørn, T Vink, ... Biotechnology progress 25 (1), 244-251, 2009 | 116 | 2009 |
| Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants PHC BERKEL, HA VEEN, MEJ GEERTS, HA BOER, JH NUIJENS Biochemical Journal 319 (1), 117-122, 1996 | 115 | 1996 |
| Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine JA Hartley, MJ Flynn, JP Bingham, S Corbett, H Reinert, A Tiberghien, ... Scientific reports 8 (1), 10479, 2018 | 109 | 2018 |
